Highlights Trevena, Inc.

Equities

TRVN

US89532E2081

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-10 EDT			5-day change	1st Jan Change
0.4157 ^USD	-1.02%		+0.75%	-42.43%

04-01	Trevena, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-01	Trevena, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Trevena, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Trevena, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04-01	CI
Trevena Inc. Receives OLINVYK Agreement with Premier, Inc	12-04	CI
Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries	11-30	CI
Trevena, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Earnings Flash (TRVN) TREVENA Posts Q3 Revenue $180,000	11-14	MT
Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study	23-10-02	CI
Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement	23-09-06	CI
Trevena, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Earnings Flash (TRVN) TREVENA Reports Q2 Revenue $3M	23-08-14	MT
Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study	23-06-26	CI
Trevena, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Earnings Flash (TRVN) TREVENA Posts Q1 Revenue $6,000, vs. Street Est of $230,000	23-05-15	MT
Trevena, Inc. Announces Partner in China, Jiangsu Nhwa Pharmaceutical Co., Ltd., Receives Formal Approval from the National Medical Products Administration for OLINVYK	23-05-08	CI
Trevena, Inc. Announces Initial Topline OLINVYK Data from Two Related Real-World Outcomes Studies	23-03-30	CI
Trevena, Inc. Initiates Targeted Proof-Of-Concept Study to Evaluate Trv045 as A Potential Treatment for Epilepsy and Other Cns Disorders	23-03-07	CI
Trevena Announces Publication of OLINVYK Respiratory Physiology Study in ANESTHESIOLOGY	23-02-14	CI
Trevena, Inc. Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement	23-01-09	CI
Trevena Regains Listing Compliance with Nasdaq Stock Market	22-11-29	MT
Trevena, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Trevena, Inc.

Equities

TRVN

US89532E2081

Highlights

Filters